Novartis $2 million gene therapy for rare disorder is world's most expensive drug https://reut.rs/2Xak1Xe Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million. http://bit.ly/hzQbMP May 25, 2019 at 01:28AM

Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.

from Reuters: Top News https://reut.rs/2Xak1Xe